TY  - GEN
AU  - Pallera,Arnel
AU  - Altman,Jessica K
AU  - Berman,Ellin
AU  - Abboud,Camille N
AU  - Bhatnagar,Bhavana
AU  - Curtin,Peter
AU  - DeAngelo,Daniel J
AU  - Gotlib,Jason
AU  - Hagelstrom,R Tanner
AU  - Hobbs,Gabriela
AU  - Jagasia,Madan
AU  - Kantarjian,Hagop M
AU  - Kropf,Patricia
AU  - Metheny,Leland
AU  - Moore,Joseph O
AU  - Ontiveros,Evelena
AU  - Purev,Enkhtsetseg
AU  - Quiery,Albert
AU  - Reddy,Vishnu V B
AU  - Rose,Michal G
AU  - Shah,Neil P
AU  - Smith,B Douglas
AU  - Snyder,David S
AU  - Sweet,Kendra L
AU  - Tibes,Raoul
AU  - Yang,David T
AU  - Gregory,Kristina
AU  - Sundar,Hema
AU  - Deininger,Michael
AU  - Radich,Jerald P
TI  - NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017
SN  - 1540-1413
PY  - 2017///1016
KW  - Abnormalities, Drug-Induced
KW  - epidemiology
KW  - Adult
KW  - Aged
KW  - Child
KW  - Evidence-Based Medicine
KW  - standards
KW  - Female
KW  - Fertility
KW  - drug effects
KW  - Humans
KW  - Leukemia, Myeloid, Chronic-Phase
KW  - drug therapy
KW  - Practice Guidelines as Topic
KW  - Pregnancy
KW  - Pregnancy Complications, Neoplastic
KW  - Prognosis
KW  - Protein Kinase Inhibitors
KW  - administration & dosage
KW  - Withholding Treatment
N1  - Publication Type: Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.6004/jnccn.2016.0162
ER  -